| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Barchas Isaac | Director | C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL | /s/ Sandra Stoneman, Attorney-in-Fact | 23 Dec 2025 | 0001808343 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMNM | Common Stock | Sale | $8,078,732 | -371,949 | -15% | $21.72 | 2,042,432 | 22 Dec 2025 | See footnotes | F1, F2, F3, F4, F5 |
| transaction | IMNM | Common Stock | Sale | $251,347 | -11,251 | -0.55% | $22.34 | 2,031,181 | 22 Dec 2025 | See footnote | F1, F5, F6, F7, F8 |
| holding | IMNM | Common Stock | 92,211 | 22 Dec 2025 | Direct | F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2024. |
| F2 | The shares were sold as follows: 226,480 shares were sold by Arsenal Bridge Venture II, LLC ("ABV II") and 145,469 shares were sold by Arsenal Bridge Venture II-B, LLC ("ABV II-B" and collectively with ABV II, the "ABV Entities"). |
| F3 | The weighted average sale price for the transaction report was $21.72, and the range of prices were between $21.31 and $22.30, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F4 | Following this transaction, ABV II and ABV II-B own 1,245,133 shares of Issuer common stock and 797,299 shares of Issuer common stock, respectively. |
| F5 | Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. |
| F6 | The shares were sold as follows: 6,851 shares were sold by ABV II and 4,400 shares were sold by ABV II-B. |
| F7 | The weighted average sale price for the transaction report was $22.34, and the range of prices were between $22.31 and $22.38, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F8 | Following this transaction, ABV II and ABV II-B own 1,238,282 shares of Issuer common stock and 792,899 shares of Issuer common stock, respectively. |
| F9 | Since the date of the Reporting Person's last ownership report, he transferred 29,469 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. |
On the basis of the relationship between Mr. Barchas and the ABV Entities, the ABV Entities may be subject to Section 16 of the Exchange Act with respect to the Issuer as so-called directors by deputization.